Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the April 2007 issue of the Archives, Soheilian et al1 discussed prophylaxis of acute posttraumatic bacterial endophthalmitis. Although the study seems well designed, I was very surprised that the prophylactic treatment included the intravitreal injection of gentamicin sulfate. Conway and Campochiaro2 (in this same journal) discussed back in 1986 how gentamicin can cause macular infarction in the setting of trauma. Again in the Archives, this time in 1989, Conway et al3 showed in primate retinas that gentamicin is definitely toxic, implying that it should never be used intraocularly. Although Soheilian and colleagues discussed studies in rabbits where gentamicin is not toxic when used in an infusion fluid, as recently as December 2005 Hancock et al4 reiterated the significant toxicity of gentamicin in both rabbit and rat retinas. With a quick literature search, at least 9 journal articles can be found discussing the significant retinal toxicity of intraocular and periocular gentamicin. I understand the need to use an antibiotic effective against gram-negative bacteria for such a trial, but the inclusion of a known toxic compound in this study makes the findings not only useless but in fact dangerous to any physician unaware of the prior research who may try to emulate what is recommended in your pages. Those who do not know history are doomed to repeat it.
Correspondence: Dr Dille, 479 Heywood Ave, Spartanburg, SC 29307 (bbdille@adelphia.net).
Financial Disclosure: None reported.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Ophthalmology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.